ViewsML / coverage
About
| When ViewsML closed its $4.9 million seed round with backing from Mayo Clinic, the story needed to reach research and drug development audiences, not just health tech readers.
SVM secured and coordinated an interview for CEO Kenneth To with Brian Buntz of R&D World. The resulting article covered Mayo Clinic’s backing of ViewsML and how the funding will advance its virtual biomarker staining technology, with the coverage also reaching Drug Discovery & Development. The interview gave To room to explain virtual biomarker staining in his own words, turning a funding announcement into a feature for scientific and R&D decision-makers. |
